G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study
Hagop M. Kantarjian,Elias Jabbour,Guillermo Garcia-Manero,Tapan M. Kadia,Courtney D. DiNardo,Naval Daver,Gautam Borthakur,Nitin Jain,Jane Waukau,Monica Kwari,Barry Douglas Anderson,Kenzo Iizuka,Cheng Jin,Chun Zhang,Farhad Ravandi,William Plunkett +15 more
TL;DR: DFP-10917 demonstrated important anti-cancer activity and safety results indicated a tolerable dose (MTD), recommended phase 2 dose (RP2D) and dose-limiting toxicities (DLT) in patients with relapsed or refractory acute leukemia, and was established at 6 mg/m2/day×14 days.
Journal ArticleDOI
Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.
Marie Robin,Liesbeth C. de Wreede,Eric Padron,Katerina Bakunina,Pierre Fenaux,Linda Koster,Aziz Nazha,Dietrich W. Beelen,Raajit K. Rampal,Katja Sockel,Rami S. Komrokji,Nico Gagelmann,Dirk-Jan Eikema,Aleksandar Radujkovic,Jürgen Finke,Victoria Potter,Sally Killick,Faezeh Legrand-Izadifar,Eric Solary,Angus Broom,Guillermo Garcia-Manero,Vittorio Rizzoli,Patrick Hayden,Mrinal M. Patnaik,Francesco Onida,Ibrahim Yakoub-Agha,Raphael Itzykson +26 more
TL;DR: Performing allo-HCT before AML transformation decreases life expectancy in lower risk patients but may be considered in higher risk patients, while a survival benefit was predicted for men with higher risk CMML.
Journal ArticleDOI
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
Shyamala C. Navada,Lewis R. Silverman,Katherine P. Hearn,Rosalie Odchimar-Reissig,Erin P. Demakos,Yesid Alvarado,Naval Daver,Courtney D. DiNardo,Marina Konopleva,Gautam Borthakur,Naveen Pemmaraju,Tapan M. Kadia,Pierre Fenaux,Steve Fruchtman,Nozar Azarnia,Guillermo Garcia-Manero +15 more
TL;DR: The combination of oral RIG and standard-dose AZA was found to be well-tolerated with evidence of efficacy in pts with MDS and marrow responses were observed in 10: marrow CR (mCR) (8), marrow PR (mPR) (2), and response data from Phase I MDS pts are updated.
Journal ArticleDOI
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship
Paul B. Koller,Hagop M. Kantarjian,Graciela M. Nogueras-González,Elias J. Jabbour,Srdan Verstovsek,Gautam Borthakur,Zeev Estrov,William G. Wierda,Guillermo Garcia-Manero,Alessandra Ferrajoli,Farhad Ravandi,Susan O'Brien,Jorge E. Cortes +12 more
TL;DR: Some patients with chronic myeloid leukemia (CML) have a history of previous malignancies and outcomes for CML diagnosed in these patients have not been well described, and this study was conducted to determine the outcome.
Journal ArticleDOI
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).
Sameer A. Parikh,Hagop M. Kantarjian,Guillermo Garcia-Manero,Elias Jabbour,Tapan M. Kadia,Farhad Ravandi,Alessandra Ferrajoli,Zeev Estrov,Jenny Feliu,Stefan Faderl +9 more
TL;DR: The current study aims to extend duration of therapy by administering lower doses of the agents and provide multiple drugs with different mechanisms of action to decrease risk of resistance to maintain high response rates and improve disease-free survival.